Effects ofSTAT3polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR‐mutation positive non‐small cell lung cancer

Autor:	Yuji Okuda, Kazuhiro Sato, Sho Sakamoto, Hayato Yokota, Masatomo Miura, Mariko Asano, Katsutoshi Nakayama, Masahide Takeda
Rok vydání:	2020
Předmět:	Male STAT3 Transcription Factor Oncology medicine.medical_specialty Lung Neoplasms Antineoplastic Agents 030226 pharmacology & pharmacy Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Gefitinib Pharmacokinetics Polymorphism (computer science) Carcinoma Non-Small-Cell Lung Internal medicine Genotype medicine Humans heterocyclic compounds Pharmacology (medical) In patient 030212 general & internal medicine skin and connective tissue diseases Lung cancer STAT3 Protein Kinase Inhibitors neoplasms Alleles Aged Pharmacology Polymorphism Genetic biology business.industry Middle Aged medicine.disease respiratory tract diseases ErbB Receptors Mutation biology.protein Female Non small cell business medicine.drug
Zdroj:	Journal of Clinical Pharmacy and Therapeutics. 45:652-659
ISSN:	1365-2710 0269-4727
DOI:	10.1111/jcpt.13173
Popis:	What is known and objective We investigated the correlations among signal transducer and activator of transcription 3 (STAT3) rs4796793C >G polymorphism, gefitinib pharmacokinetics and clinical responses in Japanese patients with non-small cell lung cancer receiving gefitinib therapy. Methods Forty-five patients were enrolled in this study. Plasma trough concentrations (C0 ) of gefitinib at the steady-state were measured by high-performance liquid chromatography. Results and discussion Patients having a gefitinib C0 of at least ≥200 ng/mL had significantly longer PFS than patients having a C0 of What is new and conclusion Clinical outcomes of gefitinib in patients with the STAT3 rs4796793C/C genotype depended on plasma concentrations of gefitinib. In addition to information regarding EGFR mutations, the STAT3 rs4796793C >G polymorphism and gefitinib C0 may be potential predictors of clinical outcomes after beginning of gefitinib therapy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5c2ca65eab19b93fbf80e27c478ee95 https://doi.org/10.1111/jcpt.13173 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.